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Abstract
The bone morphogenetic protein (BMP) family of proteins has a multitude of roles throughout the
body. In embryonic development, BMPs promote endothelial specification and subsequent venous
differentiation. The BMP pathway also plays important roles in the adult vascular endothelium,
promoting angiogenesis and mediating shear and oxidative stress. The canonical BMP pathway
functions through the Smad transcription factors; however, other intracellular signaling cascades
can be activated, and receptor complexes beyond the traditional type I and type II receptors add
additional layers of regulation. Dysregulated BMP signaling has been linked to vascular diseases,
including pulmonary hypertension and atherosclerosis. This review addresses recent advances in
the roles of BMP signaling in the endothelium and how BMPs affect endothelial dysfunction and
human disease.
BMPs in endothelial cells
The importance of the BMP (see Glossary) pathway in vascular development has been
known for years. Beyond its importance in embryonic development, critical roles have been
identified in vascular disorders, including hereditary hemorrhagic telangiectasia (HHT) and
peripheral arterial hypertension (PAH) [1]. However, the BMP pathway has functions
beyond those in endothelial differentiation, venous specification, and angiogenesis, during
development [2]. Recent studies have shown that the BMP pathway also affects processes
such as the endothelial response to hypoxia and inflammatory stimuli. These additional roles
highlight the significance of the BMP pathway in maintaining vascular homeostasis.
Of the numerous BMP ligands and receptors (see [2, 3] for detailed reviews and Table 1 for
a summary of the ligands and receptors described herein), most of them (BMPs 1, 2, 4, 6, 7,
9, and 10) have shown some effects in endothelial cells. The roles of BMP6 and BMP7 are
becoming better understood, and their contributions to human diseases such as cerebral
cavernous malformation (CCM) make these ligands crucial to study further (e.g., [4–6]).
However, this review will focus on BMPs 2, 4, and 9 due to their welldefined roles in the
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vascular endothelium and recent studies that are addressing how these specific BMP
signaling cascades affect endothelial dysfunction and human disease.
BMP2 and BMP4
Of the BMPs, BMP2 and BMP4 are best characterized. These ligands typically associate
with type I receptors BMPR1a (Alk3) or BMPR1b (Alk6) and BMPRII, leading to the
phosphorylation of Smads 1, 5, and 8 (Smad1/5/8) (Figure 1A, B; reviewed in [7]). BMP2
and BMP4 share considerable sequence homology and many functions. In bovine aortic
endothelial cells (BAECs), BMP2 and BMP4 can increase proliferation and tube formation
[8]. This effect can be inhibited by the binding of matrix Gla protein (MGP) [8], which is
enriched in the lungs and kidney; knocking out MGP increases BMP4-induced vascular
endothelial growth factor (VEGF) signaling, leading to increased lung endothelial cell
proliferation [9].
BMP9
Circulating factor BMP9 interacts with endothelially restricted Alk1 (ACVRL1), a type I
serine/threonine-protein kinase and cell-surface receptor for the TGF-beta superfamily of
ligands, as well as BMPRI [10–16]. In mouse embryonic stem cell-derived endothelial cells,
the BMP9-Alk1 interaction induces the expression of VEGFR2 and the angiopoietin
receptor, Tie2, leading to increased proliferation and tube formation [10]. Similar effects are
observed in in vivo models such as Matrigel plugs and tumor xenografts [10]. (See Text Box
1 for more detail on the in vivo models described herein.) Human umbilical vein endothelial
cells (HUVECs) show increased tube formation in response to BMP9 treatment [17], and
human pulmonary artery endothelial cells (HPAECs) show increased tube formation in
response to BMP9-induced endothelin-1 expression [18]. Although Smad4 generally acts as
a co-factor for all Smads, BMP9’s effect via endothelin-1 is Smad4-independent [18]. In
contrast with the effect of BMP9 in HUVECs and HPAECs, the BMP9-Alk1 interaction
inhibits proliferation and migration in other endothelial populations such as human dermal
microvascular endothelial cells and human aortic endothelial cells (HAECs) [7, 19]. These
differing roles suggest that additional factors determine whether BMP9 promotes or inhibits
these cellular behaviors and highlight the complexity of even a single BMP ligand.
BMP receptors
Endothelial cells express different combinations of the type I and type II BMP receptors. For
example, human microvascular endothelial cells, HUVECs, rat and mouse aortic endothelial
cells, and mouse endothelial cells that are responsive to BMP2/4, typically express either
BMPR1a or BMPR1b and BMPRII and respond to the BMP ligand by inducing Smad1/5/8
phosphorylation [20–24]. In some cases, BMPR1b associates with activin A type II receptor
(ActRIIa) [25], and BMP2-induced activation of ActRIIa leads to Smad3 activation [26]. In
contrast to BMP2/4-responsive cells, BMP9-responsive cells (e.g., mouse embryonic stem
cell-derived endothelial cells, murine embryonic endothelial cells, and human dermal
microvascular endothelial cells) express Alk1 and BMPRII [10, 13, 27]. However, Alk1
may also associate with ActRIIA and B, which can lead to the phosphorylation of either the
canonical Smad1/5 [13, 15] or Smad2 [19].
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In addition to the type I and II receptors, a new set of co-receptors, termed the type III
receptors, are being identified and characterized (Figure 1C). Endoglin is an endothelially
expressed type I glycoprotein that mediates crosstalk between integrins and the BMP family
[27]. In murine embryonic endothelial cells, fibronectin and integrin α5β1 promote
endoglin’s association with Alk1, leading to internalization via endocytosis and increased
Smad1/5 phosphorylation via BMP9 or TGF-β1 [27].
Additionally, low-density lipoprotein receptor-related protein 1 (LRP1) acts as a co-receptor
for BMPR1b and competes with BMPRII to bind to BMPR1b [22]. LRP1 directs the BMP-
receptor complex to the endocytic recycling pathway, which recycles the BMP ligand-
receptor complex back to the cell membrane, thus concentrating the BMP ligand-receptor
complex and increasing its downstream signaling [22]. Based on the numerous intracellular
cascades that can be affected via BMPs, additional co-receptors that lead to specific
cascades are anticipated.
BMP regulators
The BMP pathway comprises a diverse set of ligands, receptors, and intracellular signaling
molecules. An additional level of regulation is afforded through its numerous agonists and
antagonists. The most recently identified BMP regulator is BMP-binding endothelial
regulator (BMPER), which both promotes and inhibits signaling via BMP4, depending on
the context [28]. For example, BMPER-haploinsufficient mice show increased Smad1/5/8
phosphorylation in the greater curvature of the aortic arch and in retinal endothelial cells
compared with wild-type mice, indicating that BMPER represses canonical signaling in
these contexts [29, 30]. However, when BMP4 and BMPER associate with the LRP1/
BMPR1b dimer, BMP4 is internalized via endocytosis. As discussed above, this
internalization leads to increased Smad1/5/8 phosphorylation and explains the pro-BMP
effects of BMPER [22]. Consistent with this pro-BMP outcome, zebrafish treated with a
BMPER morpholino show a dorsalized phenotype and mispatterned intersegmental vessels,
indicating that BMPER acts as a BMP agonist during zebrafish development [31].
Although well-defined roles exist for BMP2/4 and BMP9, additional roles are continually
uncovered for additional BMP ligands. In combination with the numerous ligand-receptor
complexes and regulators, this pathway offers complex ways of regulating endothelial cell
behavior (e.g., Figure 1D–F). Thus, understanding the different components of the pathway
and how they interact will continue to be an important part of determining the effect of BMP
signaling in endothelial cells.
The role of BMP signaling during angiogenesis
BMPs typically promote angiogenesis by increasing and inducing endothelial motility and
invasion and by promoting proliferation [2]. HUVECs express the BMP receptors BMPRII
and BMPR1b at high levels, and treating HUVECs with exogenous BMP2 increases their
motility and invasion [20]. Although BAECs show decreased apoptosis in response to
BMP2 treatment [32], HUVECs do not show changes in apoptosis in response to BMP2
[20]. These differential responses may be explained by endothelial heterogeneity. Further,
the BMP ligand expression level may also be critical for regulating angiogenesis. In
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transgenic mice overexpressing BMP4 specifically in retinal pigment epithelial cells,
Smad1/5 phosphorylation is upregulated and VEGF and matrix metalloprotease-9
expression is reduced compared with wild-type mice; this reduced expression correlates with
reduced angiogenesis in a choroidal neovascularization model [33].
Supporting the importance of context in BMP function, the BMP pathway plays a role in
arterial versus venous specification. Within the caudal vein plexus, BMP2 and the BMP
receptors BMPR2a and BMPR2b are restricted to the developing cardinal vein, and axial
veins sprout in response to BMP2 [34]. This effect occurs via the R-Smads (i.e., Smad1/5/8
and Smad2/3), which promote venous sprouting, and the extracellular signal-regulated
kinases (ERKs), which promote venous sprout length [34]. Further, the clathrin-associated
sorting pathway protein disabled homolog 2 (Dab2) mediates angiogenesis in veins but not
arteries [35]. Dab2 is also restricted to venous cells in the developing zebrafish and
promotes the internalization of BMPRII via the clathrincoated pit pathway [35]. Like the
LRP1/BMPR1b–mediated internalization of BMP4 [22], the Dab2-mediated endocytosis of
BMPRII promotes downstream Smad1/5/8 phosphorylation [35].
Unlike BMP2/4, circulating BMP9 appears to have a different role. Upon activation,
platelets release BMP9, which inhibits lymphatic endothelial cell migration but has no effect
on HUVECs [36]. Interestingly, blocking circulating BMP9 increases retinal vascularization
in postnatal wild-type mouse pups, suggesting that BMP9 inhibits endothelial migration in
this context [37, 38]. A similar phenotype is observed by blocking the main receptor for
BMP9, Alk1, via adenovirus [38]. Intriguingly, global BMP9-deficient mice show no gross
defects due to the compensatory effect of BMP10 [37]. Inhibiting BMP9 in wild-type pups
with a neutralizing antibody leads to increased retinal vascular density, which is not
observed in the BMP9-deficient mouse and suggests that the antibody is cross-reactive.
However, if BMP10 signaling is also blocked in BMP9-deficient mouse pups by
administering a BMP10-neutralizing antibody, retinal expansion is blocked; in contrast, this
antibody has no effect on retinal expansion in wild-type pups, further supporting the
redundancy of BMP9 and BMP10 [37].
BMP9 and BMP10 bind to Alk1, which induces mRNA expression of the ALK1 receptor
signaling-dependent gene, transmembrane protein 100 (Tmem100), within the arteries [39].
The Tmem100-deficient mouse displays disorganized arteries and downregulated Notch/Akt
signaling [39]. Additionally, Alk1-mediated BMP9 signaling leads to the induction of Notch
pathway components Hey1 and Hey2, which repress tube formation in HUVECs [38].
Conditionally knocking out Smad1/5 in the endothelium further leads to the downregulation
of Notch pathway members, such as Hey1, Hes1, and Jagged1, and the inhibition of
sprouting in the hindbrain of E9.5 embryos [40]. Unfortunately, the early embryonic
lethality of these embryos precludes studying other aspects of vascular development [40].
Together, these defects are consistent with the role of the Notch pathway in repressing
sprouting and promoting arterial development [41] and indicate that BMP9/10 can inhibit
endothelial tube elongation by promoting the Notch pathway.
BMP9 also induces BMPER mRNA and protein expression in HAECs via its interaction
with Alk1, which feeds back to inhibit BMP9/Alk1-induced signaling [42]. BMPER
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preferentially binds to BMP9 over BMP4; thus, the BMPER-BMP9 interaction allows
BMP4/Alk2 (also known as ACVR1) signaling to remain unaltered [42]. BMPER inhibits
VEGF expression in Alk1-expressing HAECs, and the BMPER-deficient embryo shows
increased expression of the endothelial marker CD31 in overly thick vessels [42]. However,
the significance of this thickened endothelium requires further investigation.
Although the BMP family is often considered pro-angiogeneic, these experiments highlight
how context affects whether a BMP ligand is pro- or anti-angiogenic. These differences may
be due to the differential expression of co-receptors that mediate BMP internalization, which
may help explain why different endothelial cell types exhibit varying responses to the same
BMP ligands. Additional studies, particularly into coreceptors, should help clarify the
apparently contradictory roles of BMPs in angiogenesis.
The interaction between BMP signaling and oxygen in angiogenesis
Hypoxia is a major inducer of angiogenesis, and the BMP pathway mediates the endothelial
response to low oxygen. BMP9 downregulates apelin via BMPRII and the R-Smad
intracellular pathways in microvascular endothelial cells exposed to hypoxia [43]. This
downregulation blocks apelin-induced endothelial proliferation and allows hypoxia-induced
angiogenesis [43]. Upstream of the BMP ligands, BMPER is downregulated in response to
hypoxia, which relieves the BMPER-induced downregulation of BMP signaling via both the
Smad and ERK1/2 pathways [30]. In an oxygen-induced retinopathy mouse model, the
induced hypoxia leads to both decreased BMPER expression and increased vascularization
[30], supporting the role of BMPER in inhibiting angiogenesis. Additionally, both in vitro
(in HAECs) and induced myocardial infarction mouse models show that hypoxia induces the
endothelial expression of Alk1, phosphorylated Smad1/5, and endoglin [44]. Endoglin then
leads to increased BMP-response element activity and expression of Inhibitor of
differentiation (ID)1 and BCL-X (B-cell CLL/lymphoma-X, also known as BCL2-like 1),
which increase HAEC proliferation and may thus promote angiogenesis [44]. Further
supporting the protective, pro-angiogenic role of the BMP pathway, treating mice with the
BMP antagonist BMP and activin membrane-bound inhibitor (BAMBI) inhibits
neovascularization in a femoral arterial denudation injury model [45].
In addition to the effect of reduced levels of oxygen, oxidative stress can also affect vascular
function. Endothelial cells endogenously produce reactive oxygen species (ROS) through
mitochondrial electron transport chain reactions and nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase, and these low levels of ROS generally promote angiogenesis
[46]. In contrast, both chronic ROS exposure and exposure to high levels of ROS, due either
to the overproduction of ROS or a reduction in ROS scavengers, are detrimental [46].
Arteries that are exposed to disturbed flow show increased BMP4 expression and ROS
production, which lead to endothelial dysfunction [23]. BMP4 and ROS stimulate the p38-
MAP/JNK pathway, leading to caspase 3 activity and apoptosis in aortic endothelial cells
from rats and mice [23]. Additionally, treating aortic ring explants with BMP4 induces
endothelial contraction at the expense of relaxation and promotes ROS production [24]. By
binding to BMPR1A, BMP4 induces ROS production in aortic ring explants, leading to p38
activation and cyclooxygenase 2 (COX2) upregulation [24]. Additionally, BMP4-induced
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ROS via BMPR1a induces vasoconstriction in diabetic patients [47]. This constriction can
be inhibited in mouse aortic rings by blocking the BMP pathway via the antagonists noggin
and mtatin, and noggin reduces ROS levels in the aorta when administered to diabetic mice
[47].
As described herein, oxygen serves as a potent regulator of BMP-mediated endothelial cell
behavior. In response to hypoxia, BMPs 4 and 9 can promote endothelial proliferation and
angiogenesis, which would restore normal oxygen levels. Further, low levels of ROS can
promote BMP-mediated angiogenesis. In contrast, oxidative damage via ROS can lead to
BMP-mediated endothelial apoptosis and vasoconstriction. Thus, the BMP pathway must be
tightly regulated to avoid these pathological conditions.
The BMP pathway in vascular pathologies
The role of BMP signaling in hypertension
Hypertension is the leading chronic risk factor for mortality, and despite significant efforts
to control the mortality associated with hypertension, the prevalence is increasing in the U.S.
[48]. Multiple BMP ligands have well-established roles in pulmonary hypertension, and
BMP receptor mutations also affect the response to oxidative stress. BMP2/4 normally
stimulate BMPRII to promote the phosphorylation and activity of endothelial nitric oxide
synthase (eNOS) via protein kinase A activation, leading to pulmonary artery endothelial
cell (PAEC) proliferation, survival, and migration [49]. However, BMP2/4 cannot stimulate
PAECs that carry the BMPRII mutations found in patients with pulmonary arterial
hypertension (PAH) [49]. These cells exhibit decreased eNOS levels and loss of active NO,
which contribute to the PAH phenotype observed in patients with PAH [49].
In response to hypoxia-induced pulmonary hypertension, BMP2 expression increases,
leading to increased eNOS expression and activity in intrapulmonary arteries [50]. Lung
endothelial cells isolated from BMP2-haploinsufficient mice cannot induce eNOS in
response to hypoxia, and BMP2-haploinsufficient mice show more severe pulmonary
hypertension than wild-type mice [50]. Additionally, BMP2 mediates endothelial cell
survival in PAECs through the canonical Wnt pathway via binding to BMPRII, which
induces ERK phosphorylation and GSK3β activation, and through the non-canonical Wnt
pathway via binding to ActRIIa, which activates Smad3 and Rho/Rac [26]. BMP2-induced
angiogenesis occurs through both Wnt pathways, and impaired angiogenesis contributes to
vascular pathologies such as hypertension [26]. However, BMP2 can also induce Smad1
phosphorylation via binding to BMPRII or ActRIIa, leading to increased motility [26].
Despite the high amino acid sequence identity between BMP2/4 and their similar expression
patterns, BMP4-haploinsufficient mice are protected from pulmonary hypertension [50].
However, differences in expression levels or cellular localization may account for the severe
hypertensive phenotype of the BMP2-haploinsufficient mouse [50]. In addition to the
different hypertensive responses induced by the loss of BMP2/4, with loss of BMP2
exacerbating and loss of BMP4 protecting against pulmonary hypertension, excess BMP
signaling is also detrimental. Treating spontaneously hypertensive rats, which have up-
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regulated BMP4 expression, with the BMP antagonist Noggin restores endothelial relaxation
[24].
BMP9 may also contribute to the pathogenesis of PAH. BMP9 induces endothelin-1
expression in HPAECs via both Smad1 and p38 [18]. This induction inhibits endothelial cell
migration while promoting tube formation [18]. Additionally, BMP9 can bind to both Alk1
and BMPRII to stimulate endothelin-1 secretion from the pulmonary microvascular
endothelial cells via Smad1/5 and Smad2 phosphorylation, respectively [19, 51]. BMP9-
induced Smad1/5 phosphorylation leads to Id1 and Id2 mRNA expression, whereas BMP9-
induced Smad2 phosphorylation leads to interleukin-8 and E-selectin expression and
consequently inhibited DNA synthesis in HPAECs [19]. Thus, BMP9-mediated endothelin-1
expression contributes to endothelial stability and may indirectly affect PAH.
The best characterized BMP pathway member in the development of PAH is BMPRII,
which is mutated in 10–40% of patients with idiopathic and 70% of patients with familial
PAH (also known as hereditary PAH) [52]. These mutations lead to loss of function and/or
reduced expression of BMPRII [52]. PAECs from patients with these mutations show
impaired function, with increased cell death and reduced angiogenesis, leading to decreased
integration into the microvasculature when injected into severe immunodeficiency mice
[26]. BMPRII also forms a complex with peroxisome proliferator-activated receptor-gamma
and β-catenin, which induces expression of the peptide apelin [53]. As in microvascular
endothelial cells [43], apelin promotes endothelial cell survival in PAECs and inhibits
pulmonary artery smooth muscle proliferation [53]. Thus, based on the reduction in BMPRII
in patients with PAH [52], it is unsurprising that these patients also show diminished levels
of apelin [53].
The well-characterized role of BMPRII in PAH has allowed the investigation of
pharmacological interventions. The immunosuppressant FK506 (i.e., tacrolimus) binds to
the BMP repressor FKBP12, thus relieving FKBP12’s repression of the BMP pathway and
promoting BMP signaling via Alk1, 2, and 3 [54]. This derepression leads to Smad1/5 and
MAPK activity [54]. BMPRII signaling via the canonical Smads and the MAPK pathway
can be rescued in PAECs isolated from patients with idiopathic PAH by low-dose treatment
with FK506 [54]. Further, administering FK506 to inducible endothelial-specific BMPRII-
deficient mice protects them from developing PAH [54].
The role of BMP signaling in vascular disorders
One of the clearest examples of a BMP-mediated vascular disorder is HHT. This disorder is
caused by abnormal endothelial cell proliferation and smooth muscle recruitment, leading to
arteriovenous malformations and leaky vessels [1]. Thus far, three genes (endoglin, Alk1,
and Smad4) have been associated with HHT, all of which participate in the BMP pathway
[1]. In pulmonary endothelial cells, BMP9-stimulated Alk1 inhibits FGF-induced migration
as well as tube formation, suggesting that excess migration may contribute to the vascular
anomalies observed in patients with Alk1 mutations [55]. Cross-talk with the Notch pathway
has also been implicated, with Smadinduced Notch signaling leading to an inhibition of
VEGF and, consequently, inhibited cell sprouting [38]. Although Notch pathway mutations
have not been associated with HTT specifically, the Notch ligands Jagged1 and 2 are up-
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regulated in a mouse model of cerebral arteriovenous malformations [56], supporting the
importance of this pathway as well. Intriguingly, though, the BMP antagonist MGP also
plays a role in titrating the level of BMP signaling [9]. Mice that are deficient for MGP
show increased BMP signaling, as expected, but also the arteriovenous malformations that
are characteristic of HHT [9]. Together, these results stress the importance of the dose of
BMP signaling in promoting normal vascular formation.
The role of BMP signaling in atherosclerosis
Atherosclerosis is a major problem in the U.S., with prevalence ranging from 35–70%
depending on ethnicity and gender [57]. Myriad factors influence atherosclerosis, and the
BMP pathway is involved in many of these processes. One of the major mouse models of
atherosclerosis is the ApoE-deficient mouse. ApoE-deficient mice have high expression
levels of Hsp70, which binds to MGP and prevent it from inhibiting BMP2/4 [8]. In BAECs,
this enhanced BMP signaling leads to increased proliferation and tube formation along with
increased calcium secretion, which are consistent with the development of atherosclerotic
plaques [8]. Overexpressing MGP reduces canonical BMP signaling, leading to reduced
lesions and calcification in ApoE-deficient mice on a high-fat diet [58]. This increased MGP
signaling suppresses VEGF, Alk1, and inflammation markers such as intercellular adhesion
molecule 1 (ICAM) [58]. In contrast, the phenotype of the MGP-deficient mouse is too
severe to cross with the ApoE-deficient mouse and subject to a high-fat diet [58]. The MGP-
deficient mouse displays atherosclerosis that is comparable to the ApoE-deficient mouse on
a high-fat diet, and MGP-deficient mice display increased BMP signaling, including
increased Smad1/5/8 phosphorylation and expression of VEGF and Alk1 [58].
The endothelial dysfunction that underlies atherosclerosis has numerous causes. Certain
forms of shear stress lead to inflammation, thickening of the arterial wall, and the formation
of cholesterol-filled plaques in the arteries [59]. Importantly, the BMP pathway plays a role
in all these steps, as described in the following sections.
Shear stress-induced BMP signaling—Similarly to how ROS can have both positive
and negative effects depending on the dose, the shear stress caused by blood flow can also
induce different effects. Laminar shear stress, which is present in high-flow arteries that are
at low risk of developing atherosclerotic plaques, inhibits BMP4 [60]. In contrast, oscillatory
shear stress is found in arteries with disturbed flow, is associated with the development of
atherosclerotic plaques, and induces BMP4 expression [61]. Additionally, BMPRII mediates
association between BMPR1b and integrin αVβ3 in endothelial cells in response to
oscillatory shear stress [62]. The BMPR1b–integrin αVβ3 interaction activates the
Shc/FAK/ERK pathway, which consequently activates Smad1/5 [62]. This signaling cascade
leads to endothelial proliferation, which is one of the earliest steps in atherosclerotic plaque
formation, via Runx2, mTOR, and p70S6K [62] and links the BMP pathway to
mechanotransductive transmembrane proteins that respond to shear stress [63].
BMPER-haploinsufficiency accelerates atherosclerotic development in ApoE-deficient mice
on a high-fat diet [29]. siRNA-mediated knockdown of BMPER in HUVECs leads to
increased expression of the inflammatory markers ICAM and vascular cell adhesion
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molecule 1 (VCAM) in response to oscillatory shear stress and “healthy” laminar shear
stress [29]. Further supporting its protective role, BMPER promotes eNOS expression in
HUVECs under laminar shear stress [29]; eNOS has protective effects in the endothelium,
particularly during ischemia and reperfusion [64].
Inflammation and BMP signaling—BMP2 induces inflammation in HUVECs by
inducing the expression of ICAM-1 and NF-kB. In HUVECs, TNF-α and NF-kB can
downregulate BMPER at the mRNA level during the inflammatory response, which leads to
increased expression of inflammation markers ICAM-1 and VCAM-1 and decreased
expression of eNOS [65]. A similar downregulation of BMPER mRNA is observed in an
LPS-induced inflammation model in mice [65]. In support of BMPER’s anti-inflammatory
role, BMPER-haploinsufficient mice have reduced eNOS levels and exhibit
proinflammatory phenotypes compared with wild-type mice [65].
Pharmacologically, BMP-mediated inflammation can be ameliorated by statins. Mevastatin
promotes BMPER expression in HUVECs and C57/Bl6 mice by inactivating RhoA and
stabilizing BMPER mRNA [66]. Thus, inactivating RhoA leads to increased BMPER
expression, which inhibits ICAM-1 expression in HUVECs [66]. Additionally, mevastatin
downregulates BMP4 at the mRNA and protein level in HUVECs [66], further increasing
the BMPER:BMP ratio that protects blood vessels from inflammation and highlighting the
dose-dependent context through which BMPER serves as a pro- or anti-BMP regulator [28].
In addition to BMPRII’s role in PAH, BMPRII has an anti-inflammatory function.
Proatherogenic flow (i.e., oscillatory shear stress) inhibits BMPRII expression, whereas
antiatherogenic flow (i.e., laminar shear stress) promotes BMPRII expression [67]. BMPRII
expression is downregulated in patients with coronary artery disease with atherosclerotic
plaques [67]. BMPRII-haploinsufficiency accelerates atherosclerosis in ApoE-deficient
mice, even when the mice are maintained on a normal diet [67]. In HUVECs, BMPRII
knockdown inhibits BMP signaling through Smad1/5/8, thus increasing ICAM expression
and leukocyte adhesion [67]. BMPRII knockdown also results in increased ROS production
and Nox1 expression via NF-kB [67]. Of the BMP receptors, BMPRII is the only known
receptor to protect against inflammation [67].
The effect of cholesterol on BMP signaling—In addition to being upregulated by
proatherogenic flow and inflammation, BMP2 expression is induced by oxidized low-
density lipoprotein (LDL) in coronary artery endothelial cells and human arterial endothelial
cells [68, 69]. In human arterial endothelial cells, BMP2 is the only BMP ligand to be
upregulated at the mRNA level by oxidized LDL [68]. In coronary artery endothelial cells,
this induction occurs through toll-like receptors 2 and 4, which stimulate the
proinflammatory NF-kB and ERK pathways [69]. Intriguingly, oxidized LDL does not
stimulate inflammatory cytokine production in these cells, suggesting that NF-kB and ERK
instead promote coronary artery calcification, which exacerbates plaque formation [69].
The small molecule LDN-193189 inhibits BMP signaling and leads to downregulated ROS
production via oxidized LDL [68]. When administered to either LDL receptor (LDLR)-
deficient mice or wild-type mice on a high-fat diet, LDN-193189 decreases LDL synthesis
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and protects against hepatic steatosis (i.e., inflammation of the liver) [68]. This small
molecule also inhibits lesion formation and arterial calcification in the LDLR-deficient mice
independently of changes in body size. Because obesity can cause lesion formation and
arterial calcification, this lack of change in size in the treated LDLR-deficient mice
precludes improved health as the cause of these ameliorations [68].
Together, these studies show that the BMP pathway can have both protective effects, as in
PAH, and antagonistic effects, as in atherosclerosis. Although the same major BMPs are
involved in both cases, the differing outcomes suggest that additional players, such as the
receptors, must have significant roles in determining the outcome. These effects are
beginning to be elucidated, for example through the recent studies on the regulator BMPER,
but additional work is necessary to truly understand the intracellular mechanisms.
Concluding remarks
As one of the major signaling pathways in endothelial cells, the BMP pathway is
understandably complex, as highlighted by the number of ligands, the diversity of receptors,
and the myriad functions and intracellular cascades that it affects. This intricate pathway is
essential for endothelial homeostasis and responding to both normal stressors (e.g., laminar
shear and oxidative stress) and abnormal stressors (e.g., inflammation, hypoxia, and
hypertension). The BMP pathway has been implicated in disorders ranging from CCM and
chronic kidney disease to cancer. This diversity exemplifies the need for careful future
investigations to determine how the environmental context and specific endothelial
populations work together to result in a healthy vasculature. This future work is also crucial
for elucidating the specific intracellular signals that are affected in pathologies such as
hypertension and atherosclerosis, which will allow for more targeted therapeutic approaches.
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glossary
Angiogenesis the process of generating new blood vessels from existing
blood vessels; requires endothelial proliferation, sprouting and
migration from existing vessels, and tube formation in the
next destination
BAECs bovine arterial endothelial cells
Bone morphogenetic
protein (BMP)




a family of transmembrane serine/threonine kinases that
include type I (BMPR1A) and type II receptor (BMPR1B,
BMPR2)
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characterized by having a collection of large, irregularly
shaped veins that typically have thin walls and no supporting
tissue, making them prone to leaking
Endoglin a type I glycoprotein that is restricted to the endothelium; also
known as a type III BMP receptor
Endothelial nitric oxide
synthase (eNOS)
a calcium-dependent nitric oxide synthase isoform that is
restricted to endothelial cells
Extracellular signal-
regulated kinase (ERK)
one branch of the MAP kinase pathway




characterized by permanently dilated vessels, predominantly
in the skin and mucosa, and gastrointestinal bleeding
HPAECS human pulmonary artery endothelial cells
HUVECs human umbilical vein endothelial cells
Laminar shear stress the stress caused by steady, typically high-velocity blood flow
MGP matrix Gla protein
Mitogen-activated
protein kinase (MAPK)
a superfamily of protein-serine-threonine kinases activated by
numerous stimuli
Oscillatory shear stress the stress caused by turbulent, non-laminar blood flow
PAECs pulmonary artery endothelial cells
Pulmonary arterial
hypertension (PAH)
increased vascular resistance within the pulmonary circulation
Sprouting an invasive endothelial behavior that involves identifying a
single leading cell that will migrate away from an existing
vessel and bring its neighboring cells to form new vessels; the
leading tip cell signals via the Notch pathway to inhibit the
following (stalk) neighbor cells from also becoming tip cells
Vascular endothelial
growth factor (VEGF)
a family of growth factors that specifically stimulates vascular
growth and angiogenesis
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Text box 1: Models of angiogenesis
Numerous in vivo models are used to study angiogenesis. Three of these models include
tumor xenografts, Matrigel plugs, and retinopathy models. Herein, these models will be
briefly described, including benefits and disadvantages.
Xenograft model
In the xenograft model, human tumor cells are injected into a host mouse or rat. These
cells can then be followed as they graft into the host animal and form a tumor. This
model is incredibly easy for investigating tumor growth, which can be measured based on
size and weight. Further, the overall vascularization of the tumor can be grossly assessed
by excision, followed by more detailed histology if desired. An additional benefit of this
model is that novel test compounds can be evaluated for whether they inhibit vascular
recruitment to the growing tumor or whether they affect the endothelial cells after
connecting to the host vasculature. However, not all injected tumor cells will successfully
form a tumor [70].
Matrigel plug model
Similarly, in the Matrigel plug model, the commercially available extracellular matrix
product Matrigel is mixed with a chemical or cell type of interest and then injected into a
host animal. One advantage of Matrigel is that it is liquid at 4°C, allowing it to be mixed
with other reagents, and then forms a solid gel at 37°C. Thus, the injected Matrigel forms
a “plug” that can be invaginated like a tumor. However, to visualize the vasculature, the
plug must be excised and subjected to histological analysis [70].
Retinopathy model
The retinal vascular plexus forms following a stereotypical radial pattern, which makes
abnormal developmental patterns easy to identify. Premature infants often require
hyperoxic environments, which lead to vascular obliteration in the retina until the infant
is returned to a normoxic – now relatively hypoxic – environment. Although the
relatively hypoxic environment stimulates neovascularization, these changes can lead to
prematurity of retinopathy, a major cause of acquired blindness. To study this process in
mouse, mouse litters can be maintained under hyperoxic conditions, which cause the
retinal vasculature to regress. When the pups are returned to a normoxic environment,
this environment is again relatively hypoxic, and vascular growth is stimulated. Using
this model, genetic mouse models and applied agents can be tested for their effects on
preventing vascular regression or affecting the rate of neovascularization. One caveat is
that the retinal dissections are particularly delicate [71].
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• In addition to BMP2 and BMP4, BMP9 plays crucial, context-specific roles in
the endothelium.
• The recently coined “type III” co-receptors interact with the type I and type II
receptors and typically lead to endocytotic recycling of the BMP/BMP receptor
complex.
• BMPs activate different intracellular signaling cascades that plays key roles in
hypertension, vascular disorders, and atherosclerosis.
Dyer et al. Page 17






















Figure 1. An overview of the canonical BMP pathway
(A) In the absence of BMP binding (top panel), BMP receptors type I and II do not
associate, and the Smad transcription factors remain in the cytoplasm. (B) BMP typically
binds to the type II receptor (bottom panel), which allows type I and II receptors dimerize
and the type II receptor to phosphorylate the type I receptor. However, in some cases, the
BMP ligand has a higher affinity for the type I receptor, and this binding will then induce
dimerization and subsequent phosphorylation. This phosphorylation of the type I receptor
leads to the phosphorylation of downstream Smads, canonically Smads 1/5/8, which then
associate with the co-Smad, Smad4, and translocate into the nucleus. The Smad complex
will bind to BMP response elements and induce the transcription of downstream targets. (C)
The recently discovered type III receptors can compete with the type II receptors and form a
complex with the type I receptors. This association leads to endocytosis-mediated recycling
of the ligand-receptor complex to the membrane, which amplifies the BMP signaling
pathway. (D–F) Although the canonical pathway is seemingly straightforward, a single
ligand can have numerous effects and outcomes in endothelial cells. Depicted here are the
effects of BMP2 (D), BMP4 (E), and BMP9 (F) specifically via BMPRII. Each ligand can
signal through the canonical Smad1 or through a different intracellular cascade. Further,
even a single ligand can have opposing effects on a single behavior (e.g., BMP9 and
proliferation) via the intracellular signaling cascade that is activated. For simplicity, type I
and type III receptors, if identified, as well as downstream targets have been omitted.
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